If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

Amelenodor is under clinical development by AbbVie and currently in Phase I for Crohn's Disease (Regional Enteritis).

ABBV-291 is under development for the treatment of relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and ...

Shares of AbbVie Inc. ABBV inched 0.99% higher to $181.22 Friday, on what proved to be an all-around favorable trading ...

Old Port Advisors lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.7% in the 4th quarter, ...

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where ...

AbbVie (NYSE: ABBV ) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings ...

In its Q3 2024 investor letter, Polaris Global Equity Strategy discussed the strong performance of the US biopharma sector, ...

So if you can make peace with those two factors, AbbVie's stock is worth buying today. Just remember that it's the most ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $179.44 which represents a slight increase of $1.74 or 0.98% from the prior close of $177.7. The stock opened at $178.66 and touched a ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...